Ultragenyx Pharmaceutical Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Should l Buy RARE?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ultragenyx Pharmaceutical (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants misled investors regarding the efficacy of setrusumab (UX 143) in treating Osteogenesis Imperfecta (OI), leading to inflated stock purchases and subsequent investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in this field.
- Investor Advisory: Investors are advised to carefully select legal counsel, as many firms issuing notices lack actual litigation experience and may merely act as intermediaries, thus emphasizing the importance of choosing a firm with a proven success record to protect their interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.460
Low
35.00
Averages
61.65
High
120.00
Current: 21.460
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Pharmaceutical Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ultragenyx Pharmaceutical (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants misled investors regarding the efficacy of setrusumab (UX 143) in treating Osteogenesis Imperfecta (OI), leading to inflated stock purchases and subsequent investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in this field.
- Investor Advisory: Investors are advised to carefully select legal counsel, as many firms issuing notices lack actual litigation experience and may merely act as intermediaries, thus emphasizing the importance of choosing a firm with a proven success record to protect their interests.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical for violations of securities laws, concerning securities purchases between August 3, 2023, and December 26, 2025, with a deadline to contact the firm by April 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its understanding of the effects of its drug candidate on Osteogenesis Imperfecta patients, leading to an overly optimistic outlook that misled investors and affected market confidence.
- Clinical Trial Failure: The Phase III ORBIT study revealed that Ultragenyx failed to achieve a statistically significant reduction in annualized fracture rate, highlighting significant errors in the company's drug efficacy claims and exacerbating investor losses.
- Legal Consequences: As the market learned the truth about Ultragenyx, investors suffered damages, prompting the Schall Law Firm, which specializes in securities class actions, to assist affected shareholders in recovering their losses.
See More
Faruqi & Faruqi Investigates Ultragenyx Securities Claims
- Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc, covering the period from August 3, 2023, to December 26, 2025, indicating that investors may face significant losses.
- Legal Rights Reminder: The firm emphasizes that investors who purchased or acquired Ultragenyx securities during this timeframe should contact attorneys promptly to discuss their legal rights, highlighting the importance of protecting investor interests.
- Class Action Deadline: Investors should be aware that the deadline to seek the role of lead plaintiff in the federal securities class action is April 6, 2026, underscoring the urgency for timely action to safeguard their interests.
- Contact Information Provided: Securities Litigation Partner Josh Wilson has made direct contact numbers available, encouraging affected investors to call 877-247-4292 or 212-983-9330 (Ext. 1310) for further information and assistance.
See More
Ultragenyx Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, must file lead plaintiff applications by April 6, 2026, to participate in the securities class action lawsuit.
- Legal Allegations: Ultragenyx and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could lead to significant investor losses.
- Stock Price Plunge: Following the announcement on December 26, 2025, that setrusumab (UX143) failed to show significant efficacy in clinical trials, Ultragenyx's stock price plummeted approximately 42%, from $34.19 to $19.72, severely impacting the company's market capitalization.
- Case Information: The lawsuit is titled Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097, and investors can access further legal support and information through ClaimsFiler.
See More
Ultragenyx Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased Ultragenyx Pharmaceutical Inc. stock between August 3, 2023, and December 26, 2025, can seek lead plaintiff status in a class action lawsuit, indicating strong investor concern over potential violations.
- Stock Price Plunge: Following the July 9, 2025, announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock fell over 25%, and after the December 29, 2025, revelation of further study failures, the stock dropped more than 42%, reflecting a pessimistic market outlook.
- False Statement Allegations: The lawsuit alleges that Ultragenyx and its executives made false or misleading statements during the class period, failing to disclose risks associated with Osteogenesis Imperfecta studies, which may have misled investors and impacted future financing capabilities.
- Legal Process Overview: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Ultragenyx stock during the class period can apply to be the lead plaintiff, representing other investors in the lawsuit, highlighting the legal mechanisms in place to protect investor rights.
See More
Ultragenyx Pharmaceutical Accused of Misleading Investors in Class Action
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stock between August 3, 2023, and December 26, 2025, alleging the company misled investors regarding clinical trial results.
- Study Results Failure: On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies did not achieve statistical significance on primary endpoints, causing the stock price to plummet approximately 42.32% in a single day, from $34.19 to $19.72, severely impacting investor confidence.
- Misleading Statements: The lawsuit alleges that Ultragenyx made overly optimistic statements about setrusumab's potential while concealing the lack of correlation between increased bone density and reduced fracture rates, leading investors to purchase shares at artificially inflated prices.
- Shareholder Action Recommended: Affected shareholders are encouraged to contact Robbins LLP to participate in the class action as lead plaintiffs, representing other shareholders in the litigation without incurring any fees, demonstrating the firm's commitment to shareholder rights.
See More
Ultragenyx Pharmaceutical Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ultragenyx Pharmaceutical (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants misled investors regarding the efficacy of setrusumab (UX 143) in treating Osteogenesis Imperfecta (OI), leading to inflated stock purchases and subsequent investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in this field.
- Investor Advisory: Investors are advised to carefully select legal counsel, as many firms issuing notices lack actual litigation experience and may merely act as intermediaries, thus emphasizing the importance of choosing a firm with a proven success record to protect their interests.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical for violations of securities laws, concerning securities purchases between August 3, 2023, and December 26, 2025, with a deadline to contact the firm by April 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its understanding of the effects of its drug candidate on Osteogenesis Imperfecta patients, leading to an overly optimistic outlook that misled investors and affected market confidence.
- Clinical Trial Failure: The Phase III ORBIT study revealed that Ultragenyx failed to achieve a statistically significant reduction in annualized fracture rate, highlighting significant errors in the company's drug efficacy claims and exacerbating investor losses.
- Legal Consequences: As the market learned the truth about Ultragenyx, investors suffered damages, prompting the Schall Law Firm, which specializes in securities class actions, to assist affected shareholders in recovering their losses.
See More
Faruqi & Faruqi Investigates Ultragenyx Securities Claims
- Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc, covering the period from August 3, 2023, to December 26, 2025, indicating that investors may face significant losses.
- Legal Rights Reminder: The firm emphasizes that investors who purchased or acquired Ultragenyx securities during this timeframe should contact attorneys promptly to discuss their legal rights, highlighting the importance of protecting investor interests.
- Class Action Deadline: Investors should be aware that the deadline to seek the role of lead plaintiff in the federal securities class action is April 6, 2026, underscoring the urgency for timely action to safeguard their interests.
- Contact Information Provided: Securities Litigation Partner Josh Wilson has made direct contact numbers available, encouraging affected investors to call 877-247-4292 or 212-983-9330 (Ext. 1310) for further information and assistance.
See More
Ultragenyx Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, must file lead plaintiff applications by April 6, 2026, to participate in the securities class action lawsuit.
- Legal Allegations: Ultragenyx and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could lead to significant investor losses.
- Stock Price Plunge: Following the announcement on December 26, 2025, that setrusumab (UX143) failed to show significant efficacy in clinical trials, Ultragenyx's stock price plummeted approximately 42%, from $34.19 to $19.72, severely impacting the company's market capitalization.
- Case Information: The lawsuit is titled Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097, and investors can access further legal support and information through ClaimsFiler.
See More
Ultragenyx Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased Ultragenyx Pharmaceutical Inc. stock between August 3, 2023, and December 26, 2025, can seek lead plaintiff status in a class action lawsuit, indicating strong investor concern over potential violations.
- Stock Price Plunge: Following the July 9, 2025, announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock fell over 25%, and after the December 29, 2025, revelation of further study failures, the stock dropped more than 42%, reflecting a pessimistic market outlook.
- False Statement Allegations: The lawsuit alleges that Ultragenyx and its executives made false or misleading statements during the class period, failing to disclose risks associated with Osteogenesis Imperfecta studies, which may have misled investors and impacted future financing capabilities.
- Legal Process Overview: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Ultragenyx stock during the class period can apply to be the lead plaintiff, representing other investors in the lawsuit, highlighting the legal mechanisms in place to protect investor rights.
See More
Ultragenyx Pharmaceutical Accused of Misleading Investors in Class Action
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stock between August 3, 2023, and December 26, 2025, alleging the company misled investors regarding clinical trial results.
- Study Results Failure: On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies did not achieve statistical significance on primary endpoints, causing the stock price to plummet approximately 42.32% in a single day, from $34.19 to $19.72, severely impacting investor confidence.
- Misleading Statements: The lawsuit alleges that Ultragenyx made overly optimistic statements about setrusumab's potential while concealing the lack of correlation between increased bone density and reduced fracture rates, leading investors to purchase shares at artificially inflated prices.
- Shareholder Action Recommended: Affected shareholders are encouraged to contact Robbins LLP to participate in the class action as lead plaintiffs, representing other shareholders in the litigation without incurring any fees, demonstrating the firm's commitment to shareholder rights.
See More
